NO950799L - Oralt administrerbare farmasöytiske preparater - Google Patents

Oralt administrerbare farmasöytiske preparater

Info

Publication number
NO950799L
NO950799L NO950799A NO950799A NO950799L NO 950799 L NO950799 L NO 950799L NO 950799 A NO950799 A NO 950799A NO 950799 A NO950799 A NO 950799A NO 950799 L NO950799 L NO 950799L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparations
orally administrable
administrable pharmaceutical
raloxifene
ethers
Prior art date
Application number
NO950799A
Other languages
English (en)
Other versions
NO314286B1 (no
NO950799D0 (no
Inventor
Lowell Lee Gibson
Kerry John Hartauer
Julian Larry Stowers
Stephanie Ann Sweetana
Arvind Lavji Thakkar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO950799D0 publication Critical patent/NO950799D0/no
Publication of NO950799L publication Critical patent/NO950799L/no
Publication of NO314286B1 publication Critical patent/NO314286B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO19950799A 1994-03-02 1995-03-01 Oralt administrerbart farmasöytisk preparat NO314286B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20491594A 1994-03-02 1994-03-02
SG1997000220A SG65636A1 (en) 1994-03-02 1997-01-30 Orally administrable pharmaceutical formulations

Publications (3)

Publication Number Publication Date
NO950799D0 NO950799D0 (no) 1995-03-01
NO950799L true NO950799L (no) 1995-09-04
NO314286B1 NO314286B1 (no) 2003-03-03

Family

ID=26665140

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19950799A NO314286B1 (no) 1994-03-02 1995-03-01 Oralt administrerbart farmasöytisk preparat

Country Status (22)

Country Link
EP (1) EP0670162B1 (no)
JP (1) JP3574210B2 (no)
CN (1) CN1098684C (no)
AT (1) ATE211910T1 (no)
AU (1) AU684882B2 (no)
BR (1) BR9500758A (no)
CA (1) CA2143263C (no)
CZ (1) CZ286119B6 (no)
DE (1) DE69524981T2 (no)
DK (1) DK0670162T3 (no)
ES (1) ES2166799T3 (no)
FI (1) FI117042B (no)
HU (1) HU225418B1 (no)
IL (1) IL112746A (no)
NO (1) NO314286B1 (no)
NZ (1) NZ270588A (no)
PL (1) PL178858B1 (no)
PT (1) PT670162E (no)
RU (1) RU2118540C1 (no)
SG (1) SG65636A1 (no)
SI (1) SI0670162T1 (no)
ZA (1) ZA951497B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
TR199801915T2 (xx) * 1996-03-26 1998-12-21 Eli Lilly And Company Benzotiofenler, bunlar� ihtiva eden form�lasyonlar ve y�ntemler.
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
YU42397A (sh) * 1996-10-30 2000-10-30 Eli Lilly And Company Korišćenje raloksifena za pripremu leka
RU2203060C2 (ru) 1996-10-30 2003-04-27 Эли Лилли Энд Компани Способ профилактики рака молочной железы
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
KR100576149B1 (ko) 1999-12-13 2006-05-03 추가이 세이야쿠 가부시키가이샤 하이드록시카보닐-할로게노알킬 측쇄를 갖는 화합물
JP4798924B2 (ja) * 1999-12-13 2011-10-19 中外製薬株式会社 ヒドロキシカルボニル−ハロゲノアルキル側鎖を有する化合物
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
AU2002316855B2 (en) * 2001-04-24 2008-03-13 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and TNFalpha
ATE541840T1 (de) 2002-09-30 2012-02-15 Gea Farmaceutisk Fabrik As Raloxifene-l-lactat oder ein hemihydrat davon, deren verwendungen, pharmazeutischen zusammensetzungen und herstellungsverfahren
US20050008704A1 (en) * 2003-07-11 2005-01-13 Ray Anup Kumar Pharmaceutical composition for solubility enhancement of hydrophobic drugs
EP2054042B8 (en) 2006-06-30 2020-06-10 iCeutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
WO2009049643A1 (en) * 2007-10-16 2009-04-23 Pharmathen S.A. Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
WO2009080364A1 (en) * 2007-12-21 2009-07-02 Synthon B.V. Raloxifene composition
CN103932988A (zh) 2009-04-24 2014-07-23 伊休蒂卡有限公司 吲哚美辛的新剂型
WO2011000581A2 (en) 2009-07-02 2011-01-06 Synthon B.V. Raloxifene composition
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN103006570B (zh) * 2012-10-08 2013-12-25 孙维会 一种阿佐昔芬速释微丸及其制备方法
US9561186B2 (en) 2012-11-30 2017-02-07 Pharmathen S.A. Method for improving the bioavailability of low aqueous solubility drugs
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
KR102612983B1 (ko) * 2016-09-30 2023-12-13 한미약품 주식회사 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
FI950947A0 (fi) 1995-03-01
AU684882B2 (en) 1998-01-08
BR9500758A (pt) 1995-10-24
SG65636A1 (en) 1999-06-22
CA2143263C (en) 2002-01-08
HU225418B1 (en) 2006-11-28
SI0670162T1 (en) 2002-06-30
EP0670162B1 (en) 2002-01-16
DE69524981D1 (de) 2002-02-21
RU2118540C1 (ru) 1998-09-10
ZA951497B (en) 1996-08-23
PL178858B1 (pl) 2000-06-30
CN1098684C (zh) 2003-01-15
NO314286B1 (no) 2003-03-03
JP3574210B2 (ja) 2004-10-06
HU9500635D0 (en) 1995-04-28
CZ49995A3 (en) 1995-10-18
DK0670162T3 (da) 2002-03-11
CZ286119B6 (cs) 2000-01-12
NO950799D0 (no) 1995-03-01
PT670162E (pt) 2002-06-28
EP0670162A1 (en) 1995-09-06
FI950947A (fi) 1995-09-03
HUT72661A (en) 1996-05-28
FI117042B (fi) 2006-05-31
CN1112420A (zh) 1995-11-29
NZ270588A (en) 1996-01-26
JPH07277973A (ja) 1995-10-24
AU1354895A (en) 1995-09-07
DE69524981T2 (de) 2002-08-29
ATE211910T1 (de) 2002-02-15
PL307491A1 (en) 1995-09-04
CA2143263A1 (en) 1995-09-03
IL112746A (en) 1999-12-31
IL112746A0 (en) 1995-05-26
ES2166799T3 (es) 2002-05-01

Similar Documents

Publication Publication Date Title
NO950799L (no) Oralt administrerbare farmasöytiske preparater
FI933248A0 (fi) Optiskt aktiva 5h-pyrrolo(3,4-b)pyrazinderat, dess framstaellning och farmaceutiska kompositioner innehaollande detta
ITBO910024A1 (it) Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
MX9203481A (es) Formulaciones.
HRP20000494B1 (en) Pharmaceutically active morpholinol
MX9102473A (es) Agentes farmaceuticos.
ITRM910696A1 (it) Composizioni farmaceutiche per l'applicazione per via nasale.
IT1227154B (it) Composizioni farmaceutiche per uso ginecologico a base di lattobacilli
FI910851A0 (fi) 3-arylkarbonyl-1h-indoler anvaendbara som terapeutiska aemnen.
DE69101931D1 (de) Pharmazeutische Zusammensetzung.
DE69115263D1 (de) Pharmazeutische zusammensetzungen.
DZ1835A1 (fr) Nouvelles formulations.
NO913035D0 (no) (2r)-2-(di(2-propyl)fosfonylmetoksy)-3-p-toluensulfonyloksy-1-trimetylacetoksypropan, fremgangsmaate for fremstilling og anvendelse derav.
TR199501082A2 (tr) Farmasötik formülasyonlar.
FI923371A (fi) En farmaceutisk formulation.
MY117590A (en) Orally administerable pharmaceutical formulations
FI903885A0 (fi) Ny oral farmaceutisk doseringsform som foerbaettrar biotillgaengligheten.
FI930967A0 (fi) Substituerade 6,7-dihydroimidazo(1,5,4-ef)(1,5)bensodiazepin-6-oner, deras framstaellning och farmaceutiska kompositioner
FI904932A (fi) Optiskt aktiva tiazetokinolin-3 -karboxylsyraderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska kompositioner.
ES1016970Y (es) Juego para promociones.
IT9021846A1 (it) Involucro pretettivo, particolarmente studiato per l'impiego in ambito ospedaliero.
FI916035A0 (fi) Ny farmaceutisk komposition.
IT1273460B (it) Formulazioni farmaceutiche ad azione antivirale per uso topico
IT8922215A0 (it) Formulazioni farmaceutiche.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees